{"created":"2025-02-18T08:40:24.670887+00:00","id":2002295,"links":{},"metadata":{"_buckets":{"deposit":"c7bb4204-c6ba-4f4b-b276-1a718746d7b3"},"_deposit":{"created_by":41,"id":"2002295","owners":[41],"pid":{"revision_id":0,"type":"depid","value":"2002295"},"status":"published"},"_oai":{"id":"oai:hiroshima.repo.nii.ac.jp:02002295","sets":["1730444908512:1730444909774"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Analysis of efficacy and safety in atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma 1)Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice 2)Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma","subitem_title_language":"en"},{"subitem_title":"切除不能進行肝細胞癌に対するアテゾリズマブ、ベバシズマブ併用療法の有効性と安全性の解析 1)実臨床における切除不能進行肝細胞癌患者に対するアテゾリズマブ、ベバシズマブ併用療法の早期の抗腫瘍効果および安全性 2)切除不能進行肝細胞癌患者に対するアテゾリズマブ、ベバシズマブ併用療法を受けた患者における早期の蛋白尿発症のリスク因子","subitem_title_language":"ja"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"安藤, 雄和","creatorNameLang":"ja"},{"creatorName":"Ando, Yuwa","creatorNameLang":"en"}],"familyNames":[{"familyName":"安藤","familyNameLang":"ja"},{"familyName":"Ando","familyNameLang":"en"}],"givenNames":[{"givenName":"雄和","givenNameLang":"ja"},{"givenName":"Yuwa","givenNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"Access Rights","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"1)Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). ","subitem_rights_language":"en"},{"subitem_rights":"2)This is the accepted manuscript version of an article published by Karger Publishers in [Liver Cancer, Published Online:November 29 2022, 251-261] and available on https://doi.org/10.1159/000528145","subitem_rights_language":"en"},{"subitem_rights":"2)This is not the published version. Please cite only the published version. ","subitem_rights_language":"en"},{"subitem_rights":"2)この論文は出版社版ではありません。引用の際には出版社版をご確認、ご利用ください。","subitem_rights_language":"ja"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_1617187087799":{"attribute_name":"Dissertation Number","attribute_value_mlt":[{"subitem_dissertationnumber":"甲第9209号"}]},"item_1617187112279":{"attribute_name":"Degree Name","attribute_value_mlt":[{"subitem_degreename":"博士(医学)","subitem_degreename_language":"ja"},{"subitem_degreename":"Doctor of Philosophy in Medical Science","subitem_degreename_language":"en"}]},"item_1617187136212":{"attribute_name":"Date Granted","attribute_value_mlt":[{"subitem_dategranted":"2023-03-23"}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_1617353299429":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_language":"en","subitem_relation_name_text":"1)Cancers 2021, 13, 3958."}]},{"subitem_relation_name":[{"subitem_relation_name_language":"en","subitem_relation_name_text":"2)Liver Cancer 251–261."}]},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.3390/cancers13163958","subitem_relation_type_select":"DOI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1159/000528145","subitem_relation_type_select":"DOI"}}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-08-22"}],"displaytype":"simple","filename":"k9209_1.pdf","filesize":[{"value":"198.7 KB"}],"mimetype":"application/pdf","url":{"objectType":"abstract","url":"https://hiroshima.repo.nii.ac.jp/record/2002295/files/k9209_1.pdf"},"version_id":"94a2fac4-0f90-4144-83a3-bf91ab27fd24"},{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-08-22"}],"displaytype":"simple","filename":"k9209_2.pdf","filesize":[{"value":"161.5 KB"}],"mimetype":"application/pdf","url":{"objectType":"abstract","url":"https://hiroshima.repo.nii.ac.jp/record/2002295/files/k9209_2.pdf"},"version_id":"7bc9653d-0eb6-4435-8ed9-1e481d9094d8"},{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-08-22"}],"displaytype":"simple","filename":"k9209_3_1.pdf","filesize":[{"value":"909.1 KB"}],"mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://hiroshima.repo.nii.ac.jp/record/2002295/files/k9209_3_1.pdf"},"version_id":"3d38e2e8-1253-4d44-8f0a-dee9d59b8058"},{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-08-22"}],"displaytype":"simple","filename":"k9209_3_2.pdf","filesize":[{"value":"1.6 MB"}],"mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://hiroshima.repo.nii.ac.jp/record/2002295/files/k9209_3_2.pdf"},"version_id":"5f5a66b1-df63-4a50-94cc-cd0499901cb4"}]},"item_1617944105607":{"attribute_name":"Degree Grantor","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"広島大学"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"15401","subitem_degreegrantor_identifier_scheme":"kakenhi"}]},{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"en","subitem_degreegrantor_name":"Hiroshima University"}]}]},"item_1732771732025":{"attribute_name":"旧ID","attribute_value":"54466"},"item_title":"Analysis of efficacy and safety in atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma 1)Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice 2)Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma","item_type_id":"40003","owner":"41","path":["1730444909774"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-08-22"},"publish_date":"2023-08-22","publish_status":"0","recid":"2002295","relation_version_is_last":true,"title":["Analysis of efficacy and safety in atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma 1)Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice 2)Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma"],"weko_creator_id":"41","weko_shared_id":-1},"updated":"2025-02-19T07:26:48.656691+00:00"}